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OBJECTIVES: For many courses of therapy, assessments of treatment effectiveness 
are used to inform treatment continuation decisions. If a “mid-therapy” assessment 
(MTA) is positive, the patient is indicated to continue treatment; if negative, treatment 
may be discontinued. Using expected utility theory, we demonstrated previously that 
the availability and timing of such assessments may inﬂ uence patients’ treatment initia-
tion decisions. We conducted a pilot study among chronic hepatitis C (CHC) patients 
to examine preferences over MTA timing and treatment initiation. METHODS: A 
stated preference survey was developed and pre-tested among 10 community volun-
teers and then administered to 49 CHC patients. The survey described two MTAs for 
CHC treatment: one at 4 weeks (rapid virologic response, RVR) and the other at 12 
weeks (early virologic response, EVR). Test characteristics varied between the two 
MTAs, but the decision algorithm (stated above) was held constant. Multiple response 
formats were used to elicit preferences across MTA and treatment initiation. Results 
are summarized as means and proportions. RESULTS: Average age was 54.6 yrs; 
55.1% were male; 32.7% were treatment-naïve; 67.3% reported their general health 
as good or better. Three subjects failed to answer one or more MTA or treatment 
choice questions. More subjects had previously heard of EVR compared to RVR 
(43.8% vs. 14.3%, p > 0.01). Given a choice between MTAs, 55.3% of subjects 
indicated a preference for RVR. Treatment utilizing RVR was somewhat or strongly 
preferred by 57.4% of subjects, and 61.2% said they would choose RVR if only one 
test was available. However, more subjects responded that they would accept treat-
ment with EVR than with RVR 60.9% vs. 55.3% (difference not signiﬁ cant). CON-
CLUSIONS: Patients with CHC consistently indicated MTA preferences that are at 
odds with current treatment guidelines. Further research is needed to understand the 
relationship between MTA preference and treatment initiation.
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OBJECTIVES: The Rome III criteria deﬁ ne pediatric irritable bowel syndrome with 
constipation (IBS-C) as abdominal pain or discomfort associated with constipation 
symptoms. Historically, few pediatric IBS-C trials have used symptom measures that 
were developed with patient input. This study aimed to develop pediatric IBS-C 
symptom measures through qualitative interviews with children with IBS-C and their 
parents/caregivers. METHODS: Children diagnosed with IBS-C (aged 6–8 [n = 10], 
9–11 [n = 10] and 12–17 [n = 10]) and their parents were interviewed. Thematic 
analysis of interview transcripts identiﬁ ed concepts. Age appropriate items and 
response options, developed to measure each concept, were reviewed by expert clini-
cians. RESULTS: IBS-C symptoms identiﬁ ed as being bothersome to children included: 
abdominal symptoms such as abdominal pain (“stomach hurts”) and bloating 
(“tummy like a balloon”), and bowel symptoms such as infrequent bowel movements 
(“don’t go often”), difﬁ culty defecating (“it won’t come out”), straining on defecation 
(“have to push hard”), rectal pain during defecation (“butt hurts”), hard stools (“hard 
and bumpy”), large stools (“it’s like a log”), and a feeling of incomplete evacuation 
(“some that won’t come out”). Saturation was achieved for the above concepts. 
Parents relied on behavioural signs of IBS-C (such as inactivity or irritability) and the 
child telling them about symptoms when assessing their child’s condition. In general 
the majority of parents and children agreed in their reports of symptoms, though there 
were some minor inconsistencies. CONCLUSIONS: Consistent with guidelines for 
patient-reported outcomes, these results were used to develop age-appropriate ques-
tions to measure both abdominal and bowel symptoms. The instrument is currently 
undergoing testing to assess patient understanding and relevance. Results from qualita-
tive interviews with children with IBS-C suggest abdominal and bowel symptoms are 
both important and bothersome to pediatric IBS-C patients and should be included in 
treatment assessments.
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Rokkas T1, Panitti E2, Nikas N2
1Henry Dunant Hospital, Athens, Attiki, Greece; 2AstraZeneca, Athens, Greece
OBJECTIVES: GERD is a common condition in daily clinical practice associated with 
reduced quality of life and impact on productivity. The aims of the current study were 
to estimate the prevalence of GERD in primary care by using a novel diagnostic tool 
(GerdQ questionnaire) and to assess the impact of the disease in productivity. 
METHODS: The Greek GerdQ study was a cross-sectional, single-visit, epidemiologi-
cal study in patients presenting to their physician with upper GI symptoms. Data on 
patients’ demographics, medical/GI history and upper GI symptoms were recorded by 
the investigators. All subjects completed the GerdQ, and those scored ≥ 8 also com-
pleted the WPAI-GERD questionnaire for the evaluation of GERD impact on produc-
tivity. RESULTS: Overall 889 (887 evaluable) patients were enrolled by 91 primary 
care physicians. 47% of patients were male. Mean (± SD) age was 51 (17) years with 
37.5% of patients presenting no previous history of GI tract disorders. The most 
prevalent GI symptoms in the week prior to study visit were heartburn, regurgitation 
and belching, presenting a high frequency (≥2 days/week or daily) in 62.4%, 47% and 
50.2% of the patients, respectively. Antisecretory treatment was reported by 62% of 
patients. Based on GerdQ, 71.8% patients had GERD (GerdQ score ≥ 8) while 45.1% 
of them were suffering from disrupting disease (GerdQ impact score ≥ 3). Mean (± 
SD) absenteeism due to GERD was 2.3 (4.9) hours/week with a mean (± SD) of 11.8 
(9.6) additional hours/week lost due to presenteeism. The observed reduction in daily 
life productivity was 37.4%. CONCLUSIONS: These data suggest that in Greece, 
GERD is a highly prevalent condition in primary care patients with upper GI symp-
toms, posing a signiﬁ cant burden to patients in terms of reduced productivity both in 
work and in daily life.
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OBJECTIVES: Gastroesophageal reﬂ ux disease (GERD) has substantial impact in 
primary care, but the optimal approach to management is uncertain. a structured 
management strategy may improve the diagnosis and therapeutic management of 
GERD, but individual studies may be limited by their focus on local strategies that 
may not be valid for other countries. METHODS: We conducted a meta-analysis of 
ﬁ ve cluster randomised clinical trials comparing a new management strategy with 
usual care in patients with GERD conducted in Austria, Italy, Norway, Spain and 
Sweden (NCT00842387). The intervention strategy was based on the self-adminis-
tered validated GerdQ questionnaire to stratify adult patients with classical symptoms 
of GERD (heartburn or regurgitation) according to the frequency and impact of 
symptoms. The most effective acid-suppressive therapy (esomeprazole 40 mg once 
daily) was used only in patients with the highest GerdQ symptom impact score (≥3). 
The primary outcome was non-response to treatment deﬁ ned as a total GerdQ score 
≥ 8 at the end of follow-up. Odds ratios for the primary outcome were combined using 
a random effects model. RESULTS: A total of 2400 patients were enrolled and average 
follow-up ranged from 4 to 18 weeks. The odds ratios for lack of treatment response 
with the structured management strategy compared with usual care ranged from 0.22 
to 0.84, across studies. The random-effects combined odds ratio for non-response to 
treatment was 0.56 (95% CI 0.22–0.90; p = 0.001), with signiﬁ cant between-study 
heterogeneity (p < 0.001). CONCLUSIONS: Stratiﬁ cation of patients according to the 
GerdQ questionnaire, using a locally adapted primary care management strategy for 
GERD signiﬁ cantly increased the likelihood of a response to treatment compared to 
usual clinical practice, although signiﬁ cant between-country heterogeneity suggests 
that GERD management can still be improved.
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OBJECTIVES: To analyze the impact of opioid induced constipation (OIC) on 
patients’ health related quality of life (HRQoL). METHODS: An observational, mul-
ticenter study was carried out in Spain. All patients were free of constipation at 
baseline and received opioids for at least 2 months. The impact of OIC on patients’ 
HRQoL was determined in a cross-sectional phase of the study. Patients were evalu-
ated depending on response to oral treatment for OIC. HRQoL was assessed by the 
following tools: the Spanish version of the EuroQoL (EQ-5D) and EuroQoL Visual 
Analogue Scale (EQ-VAS). The CVE-20 questionnaire and a speciﬁ c question were 
used to assess the perceived health status related to constipation. RESULTS: Patients 
with OIC showed a mean (SD) overall CVE-20 score of 48.0 (18.6), the time spent 
defecating and discomfort caused by a bloated stomach were highly rated in the 
general physical dimension (56.4% in both items). Laxative dependence was the most 
rated item (51.9%) in the social dimension. Regarding general QoL, EQ-5D, the 
dimension in which patients were more affected was the pain/discomfort dimension 
(89.7%). Mean EQ-VAS score (SD) was 51.3 (19.3), mean EQ-5D VAS tariff (SD) 
was 0.45 (0.25) and mean EQ-5D TE tariff (SD) was 0.38 (0.40). Overall, responders 
to oral laxatives showed a better HRQoL than non-responders. The CVE-20 question-
naire score in responders was higher than in non-responders (50.8 vs. 40.6, respec-
tively, P < 0.001). Regarding general QoL, the EQ-5D anxiety/depression was the only 
dimension signiﬁ cantly more affected in non-responders (p = 0.003). Accordingly, 
responders obtained statistically signiﬁ cant higher EQ-VAS score (SD), 53.0 (18.9) vs. 
45.5 (18.4) (p = 0.004). CONCLUSIONS: OIC is one of the most distressing opioid 
adverse events and as such, has a negative impact on HRQoL. The differences 
observed in the CVE-20 and EQ-VAS scores between responders and non-responders 
are statistically signiﬁ cant and may also have a clinical impact. 
